Andrew McDonald, MD
Hospitalist · Newnan, GANPI 1467436600
Payments from drug & device makers
Across 101 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$270
- Novo Nordisk$164
- Novartis$155
- Johnson & Johnson$146
- AbbVie$140
- GSK$134
- plus $654 from 17 others
What the payments were for
- Food & beverage$1,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 16 | $270 |
| Novo Nordisk | 10 | $164 |
| Novartis | 10 | $155 |
| Johnson & Johnson | 10 | $146 |
| AbbVie | 8 | $140 |
| GSK | 8 | $134 |
| AstraZeneca | 7 | $124 |
| Pfizer | 5 | $81 |
| Dexcom, Inc. | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Antares Pharma, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Medtronic(2 entities) | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Amgen | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$1,663 in reported general payments places this provider in the 90th percentile of 812 hospitalist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $113,522 |
| JardianceEmpagliflozin | 67 | $83,056 |
| EliquisApixaban | 79 | $65,378 |
| TrulicityDulaglutide | 13 | $25,958 |
| MyrbetriqMirabegron | 24 | $22,595 |
| EntrestoSacubitril/Valsartan | 18 | $16,702 |
| Gabapentin | 332 | $6,769 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,069 |
| Atorvastatin Calcium | 411 | $3,741 |
| Levothyroxine Sodium | 401 | $3,449 |
| Pantoprazole Sodium | 277 | $3,305 |
| SynthroidLevothyroxine Sodium | 49 | $2,927 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $2,908 |
| Famotidine | 187 | $2,796 |
| Rosuvastatin Calcium | 355 | $2,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $164 | $113,52287 claims |
| Boehringer IngelheimJardiance | $37 | $83,05667 claims |
| PfizerEliquis | $81 | $65,37879 claims |
| Lilly USA, LLCTrulicity | $35 | $25,95813 claims |
| Astellas Pharma US IncMyrbetriq | $270 | $22,59524 claims |
| NovartisEntresto | $155 | $16,70218 claims |
| AstraZenecaSymbicort | $124 | $5,06919 claims |
| AbbVieSynthroid | $140 | $2,92749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 812 hospitalist providers in Georgia.
Other hospitalist in Newnan
- Stanley SmithNewnan$6K
- James SmithNewnan$5K
- Vasundhara CheekatiLawrenceville$2.3M
- Neelima SurapaneniAtlanta$308K
- Sri Krishna MukkamalaCumming$243K
- Sara DawitRoswell$190K
- Roohi FaiyazGainesville$174K
- Kamardeen AlabiHiram$87K
- Gul MughalDuluth$33K
- Annie ParkCanton$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.